Jessica L. Mega, M.D., and David A. Morrow, M.D., M.P.H.

Dr. Morrow is Assistant Professor of Medicine, Harvard Medical School and Dr. Mega is a Cardiovascular Fellow, Harvard Medical School. Both are active investigators in the TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.

Within the past 12 months, Dr. Morrow has received research grant support from Accumetrics, Amgen, AstraZeneca, Bayer Healthcare, Beckman Coulter, Biosite, Bristol-Myers Squibb, CV Therapeutics, Eli Lilly and Company, GlaxoSmithKline, Inotek Pharmaceuticals, Integrated Therapeutics, Merck, Merck-Schering Plough Joint Venture, Millennium Pharmaceuticals, Novartis Pharmaceuticals, Nuvelo, Ortho Clinical Diagnostics, Pfizer, Roche Diagnostics, Sanofi Aventis and Schering-Plough. He has been on the Speakers Bureau of Bayer Diagnostics, Beckman-Coulter, Dade-Behring, Sanofi Aventis and Roche Diagnostics, and been a consultant/advisor to Beckman-Coulter, Critical Diagnostics, Genentech, GlaxoSmithKline, Ortho Clinical Diagnostics and Sanofi Aventis. Within the past 12 months, Dr. Mega has received research grant support from Schering Plough.

This activity is made possible by an unrestricted educational grant from .

Release Date: 01/09/2007
Termination Date: 01/09/2010

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Upon completion of this Cyberounds^®, the participant should be able to:

• Describe pathophysiologic and clinical features of diagnoses across the spectrum of acute coronary syndromes
• Discuss the role of risk stratification in the evaluation and management of patients with ACS
• Evaluate the optimal approaches for reperfusion therapy for individual patients presenting with ST elevation MI
• Integrate the evidence from clinical trials of antiplatelet and antithrombotic therapy into clinical practice.

 

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity